Live Breaking News & Updates on ஜேம்ஸ் நிலா

Stay updated with breaking news from ஜேம்ஸ் நிலா. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Immune therapy after surgery lowers relapse risk in patients with high-risk melanoma


 E-Mail
IMAGE: Kenneth Grossmann, MD, PhD, of Huntsman Cancer Institute, led the SWOG S1404 clinical trial, which found that patients with high-risk melanoma who had pembrolizumab after their surgery had a longer.
view more 
Credit: Huntsman Cancer Institute
PORTLAND, OR - Patients with high-risk melanoma who had a course of pembrolizumab after their surgery had a longer time before their disease recurred than patients who got either ipilimumab or high-dose interferon after surgery. These findings of a large SWOG Cancer Research Network clinical trial, S1404, will be presented at the ASCO annual meeting June 6, 2021.
Researchers also measured overall survival and found no statistically significant difference in overall survival rates between the two groups of patients three and one-half years after the last patient enrolled to the trial. They did find, however, that patients taking pembrolizumab had fewer serious side effects than those treated with e ....

United States , Dana Farber Cancer Institute , Megan Othus , Justinev Cohen , Johnm Kirkwood , Teresam Petrella , Antoni Ribas , Bartosz Chmielowski , Kennethf Grossmann , Kari Kendra , Pauline Funchain , Krishnas Gunturu , Thach Giao Truong , Ahmad Tarhini , Karld Lewis , Vernonk Sondak , Zeynep Eroglu , Elizabethi Buchbinder , Nikhil Khushalani , Hongli Li , Sapna Patel , Kaiser Permanente , University Of Utah Medical Center , National Cancer Institute , University Of Pittsburgh Medical Center , Ohio State University ,